Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib
Neil Parrott, Cordula Stillhart, Marc Lindenberg, et al.
The AAPS Journal (2020) Vol. 22, Iss. 4
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Ami V. Desai, Giles Robinson, Karen Gauvain, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 10, pp. 1776-1789
Open Access | Times Cited: 71
Simulating human digestion: developing our knowledge to create healthier and more sustainable foods
Alan R. Mackie, Ana-Isabel Mulet-Cabero, Amelia Torcello‐Gómez
Food & Function (2020) Vol. 11, Iss. 11, pp. 9397-9431
Open Access | Times Cited: 137
Entrectinib, a new multi-target inhibitor for cancer therapy
Qinghua Jiang, Mingxue Li, Hua Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112974-112974
Open Access | Times Cited: 51
Applications of PBPK/PBBM modeling in generic product development: An industry perspective
K Yuvaneshwari, Sivacharan Kollipara, Tausif Ahmed, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 69, pp. 103152-103152
Closed Access | Times Cited: 41
Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs
Fang Wu, Heta Shah, Min Li, et al.
The AAPS Journal (2021) Vol. 23, Iss. 2
Closed Access | Times Cited: 50
Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations
Di Wu, Jiaying Liu, Erickson M. Paragas, et al.
Drug Metabolism Reviews (2024), pp. 1-20
Closed Access | Times Cited: 5
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
Georgina Meneses‐Lorente, Darren Bentley, Elena Guerini, et al.
Investigational New Drugs (2021) Vol. 39, Iss. 3, pp. 803-811
Open Access | Times Cited: 29
Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives
Sivacharan Kollipara, Frederico Severino Martins, Maitri Sanghavi, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 2, pp. 345-358
Closed Access | Times Cited: 12
PREPARATION AND EVALUATION OF ENTRECTINIB PLGA NANOBUBBLES BY CENTRAL COMPOSITE DESIGN
P Nandini, D. V. R. N. Bhikshapathi
International Journal of Applied Pharmaceutics (2025), pp. 304-315
Open Access
Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics
Agustos C. Ozbey, Georgina Meneses‐Lorente, Brian Simmons, et al.
Clinical Pharmacokinetics (2025)
Closed Access
Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study Data
Yumi Cleary, Nicoló Milani, Kayode Ogungbenro, et al.
The AAPS Journal (2025) Vol. 27, Iss. 4
Open Access
Streamlining Food Effect Assessment — Are Repeated Food Effect Studies Needed? An IQ Analysis
Filippos Kesisoglou, Sumit Basu, Tejashree Belubbi, et al.
The AAPS Journal (2023) Vol. 25, Iss. 4
Closed Access | Times Cited: 9
Optimizing Entrectinib Nanosuspension: Quality by Design for Enhanced Oral Bioavailability and Minimized Fast-Fed Variability
S. Sreenivasa Chary, D. V. R. N. Bhikshapathi, N. Mohana Vamsi, et al.
BioNanoScience (2024) Vol. 14, Iss. 4, pp. 4551-4569
Closed Access | Times Cited: 3
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
Kenichi Umehara, Neil Parrott, Emilie Schindler, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 4, pp. 1130-1140
Closed Access | Times Cited: 3
Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective
Clive Wilson, Leon Aarons, Patrick Augustijns, et al.
European Journal of Pharmaceutical Sciences (2021) Vol. 172, pp. 106100-106100
Open Access | Times Cited: 21
Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging
Tejashree Belubbi, Davide Bassani, Cordula Stillhart, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 191-191
Open Access | Times Cited: 7
Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification
Xavier Pépin, Vivien McAlpine, Andrea Moir, et al.
Molecular Pharmaceutics (2023) Vol. 20, Iss. 4, pp. 2181-2193
Closed Access | Times Cited: 7
Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism
Seong‐Wook Seo, Dong‐Gyun Han, Eugene Choi, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112520-112520
Open Access | Times Cited: 16
Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir
Tom de Waal, Jari Rubbens, Michael Grimm, et al.
Pharmaceutics (2020) Vol. 12, Iss. 7, pp. 670-670
Open Access | Times Cited: 18
Characterization of neonatal and infant enterostomy fluids
Tom de Waal, Joachim Brouwers, Raf Mols, et al.
International Journal of Pharmaceutics (2023) Vol. 639, pp. 122943-122943
Open Access | Times Cited: 6
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
Georgina Meneses‐Lorente, Stephen Fowler, Elena Guerini, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 1, pp. 68-80
Open Access | Times Cited: 14
Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space – Part I: Adults
Xavier Pépin, Maria Hammarberg, Alexandra Mattinson, et al.
Pharmaceutical Research (2022) Vol. 40, Iss. 2, pp. 387-403
Closed Access | Times Cited: 9
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Georgina Meneses‐Lorente, Elena Guerini, François Mercier, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 91, Iss. 3, pp. 239-246
Open Access | Times Cited: 5
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
Xiaowen Wang, Fang Chen, Nan Guo, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 92, Iss. 4, pp. 253-270
Closed Access | Times Cited: 5
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making
Nassim Djebli, Vincent Buchheit, Neil Parrott, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2021) Vol. 46, Iss. 6, pp. 779-791
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top